BDSX BIODESIX INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIODESIX INC reported revenue of $26.9M (up 34.2% from a year earlier), net income of −$7.27M and diluted EPS of −$0.71; over the last four quarters revenue was $103M and net income −$27.8M; for the fiscal year ended December 2025 revenue was $88.5M, up 24.1% on the year before.
BDSX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $88.5M, gross profit n/a, operating income −$27.9M, net income −$35.3M (margin -39.9%), EPS −$4.67
- Fiscal year ended Dec 2024: revenue $71.3M, gross profit n/a, operating income −$34.5M, net income −$42.9M (margin -60.2%), EPS −$6.64
- Fiscal year ended Dec 2023: revenue $49.1M, gross profit n/a, operating income −$41.3M, net income −$52.1M (margin -106.2%), EPS −$0.64
- Fiscal year ended Dec 2022: revenue $38.2M, gross profit n/a, operating income −$50.6M, net income −$65.4M (margin -171.3%), EPS −$1.55
- Fiscal year ended Dec 2021: revenue $54.5M, gross profit n/a, operating income −$40.9M, net income −$43.2M (margin -79.2%), EPS −$1.58
BDSX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $26.9M (up 34.2% year over year), net income −$7.27M, EPS −$0.71
- Quarter ended Mar 31, 2026: revenue $25.6M (up 42.3% year over year), net income −$7.79M, EPS −$0.81
- Quarter ended Dec 31, 2025 (from the annual report): revenue $28.8M (up 40.8% year over year), net income −$3.99M, EPS −$0.43
- Quarter ended Sep 30, 2025: revenue $21.8M (up 19.9% year over year), net income −$8.72M, EPS −$1.16
- Quarter ended Jun 30, 2025: revenue $20.0M (up 11.7% year over year), net income −$11.5M, EPS −$1.56
- Quarter ended Mar 31, 2025: revenue $18.0M (up 21.2% year over year), net income −$11.1M, EPS −$1.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue $20.4M (up 39.3% year over year), net income −$8.25M, EPS −$5.02
- Quarter ended Sep 30, 2024: revenue $18.2M (up 34.5% year over year), net income −$10.3M, EPS −$1.40
- Quarter ended Jun 30, 2024: revenue $17.9M (up 51.0% year over year), net income −$10.8M, EPS −$0.08
- Quarter ended Mar 31, 2024: revenue $14.8M (up 63.6% year over year), net income −$13.6M, EPS −$0.14
- Quarter ended Dec 31, 2023 (from the annual report): revenue $14.7M (up 52.7% year over year), net income −$9.14M, EPS −$0.09
- Quarter ended Sep 30, 2023: revenue $13.5M (up 21.5% year over year), net income −$10.9M, EPS −$0.14
- Quarter ended Jun 30, 2023: revenue $11.9M (up 8.4% year over year), net income −$13.4M, EPS −$0.17
- Quarter ended Mar 31, 2023: revenue $9.06M (up 38.3% year over year), net income −$18.7M, EPS −$0.24
- Quarter ended Dec 31, 2022 (from the annual report): revenue $9.61M (up 33.0% year over year), net income −$20.3M, EPS −$0.31
- Quarter ended Sep 30, 2022: revenue $11.1M (up 70.1% year over year), net income −$13.7M, EPS −$0.34
- Quarter ended Jun 30, 2022: revenue $11.0M (down 7.9% year over year), net income −$15.8M, EPS −$0.40
- Quarter ended Mar 31, 2022: revenue $6.55M (down 77.3% year over year), net income −$15.6M, EPS −$0.50
- Quarter ended Dec 31, 2021 (from the annual report): revenue $7.22M, net income −$13.3M, EPS −$0.35
- Quarter ended Sep 30, 2021: revenue $6.53M, net income −$11.5M, EPS −$0.41
BDSX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$23.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$48.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$22.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$45.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$28.2M, share buybacks n/a
BDSX balance sheet
- Jun 30, 2026: cash $30.0M, total assets $95.3M, total liabilities $86.2M, shareholders' equity $9.14M
- Mar 31, 2026: cash $25.6M, total assets $94.6M, total liabilities $85.5M, shareholders' equity $9.13M
- Dec 31, 2025: cash $19.0M, total assets $87.5M, total liabilities $89.9M, shareholders' equity −$2.47M
- Sep 30, 2025: cash $16.6M, total assets $88.7M, total liabilities $90.4M, shareholders' equity −$1.72M
- Jun 30, 2025: cash $20.7M, total assets $87.7M, total liabilities $86.6M, shareholders' equity $1.14M
- Mar 31, 2025: cash $17.6M, total assets $86.2M, total liabilities $75.2M, shareholders' equity $11.1M
- Dec 31, 2024: cash $26.2M, total assets $97.2M, total liabilities $76.4M, shareholders' equity $20.9M
- Sep 30, 2024: cash $31.4M, total assets $103M, total liabilities $74.9M, shareholders' equity $27.9M
What is BDSX's revenue?
BIODESIX INC reported $103M of revenue over its last four quarters, through June 30, 2026.
Is BDSX profitable?
No. BIODESIX INC lost $27.8M over the last four quarters.
What is BDSX's EPS?
Diluted earnings per share over the last four quarters were −$3.11; −$0.71 in the latest quarter.